M

Researcher Profile

Mallorie H. Fiero

🏛 Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

0000-0001-5536-116x

3

Publications

94

Citations

10

Co-Authors

3

Active Years

Publications

Journal Article Journal of Clinical Oncology Mar 30, 2026

Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?

Mallorie H. Fiero · Mirat Shah · Laleh Amiri-Kordestani

10.1200/jco-26-00226

Journal Article Journal of Clinical Oncology Jul 01, 2025

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer

Mirat Shah · Ting-Yu Chen · Gwynn Ison · Mallorie H. Fiero +13 more

10.1200/jco-24-02834 14 citations

Journal Article Clinical Cancer Research Aug 04, 2022

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Mirat Shah · Christy L. Osgood · Anup K. Amatya · Mallorie H. Fiero +9 more

10.1158/1078-0432.ccr-22-1110 80 citations

Publication Timeline

2026

1

2025

1

2022

1

Frequent Co-Authors

Laleh Amiri-Kordestani

William F. Pierce

Tiffany K. Ricks